LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announced that clinical results from a single-center study showing significant improvement in near visual acuity following treatment with its proprietary, patented Raindrop™ Near Vision Inlay (formerly the Vue+® and PresbyLens®) were presented by John Olkowski, M.D., Chief Surgeon at EyeSight Hawaii, at the International Society of Presbyopia (ISOP) Fourth Annual Conference in Milan, Italy.
Significant improvement in this group of patients was observed within 7 days of treatment. Data showed that at one week following treatment with the Raindrop in the non-dominant eye, 19 of 25 subjects achieved uncorrected 20/25 or better near visual acuity with an average gain in near vision of 4 lines using the Optec 6500 visual acuity tester. Of the 12 study patients so far followed for a full year, all reported uncorrected 20/25 or better near visual acuity in the treated eye. Additionally 9 of the 12 subjects had uncorrected 20/25 or better distance visual acuity in the treated eye with no subject’s treated eye being worse than 20/32. All subjects were 20/20 or better binocularly. These data were collected as part of an ongoing Phase III clinical trial with the Raindrop in the United States. The Raindrop has received CE Mark authorization and is available in the European Union.
“Patient satisfaction at 12 months was very positive with 9 patients reporting to be ‘completely satisfied,’ 3 were ‘very satisfied’ and 1 was ‘somewhat satisfied,’” said Dr. Olkowski. “Additionally, these 12 subjects reported a very low number of symptoms in the visual and discomfort categories, with little change from those reported at pre-operative levels. Even for the worst symptoms in each category, halos and dryness, none was above the level of ‘moderate.’”
“Once again, we are seeing the ‘WOW effect’ produced by the Raindrop with strong visual acuity results soon after treatment, stable results after one year and exceptional patient satisfaction,” said RVO President and CEO John Kilcoyne. “We thank Dr. Olkowski for presenting these favorable results at ISOP.”
The theme of patient satisfaction was revisited by RVO Vice President of Research & Development Keith Holliday, Ph.D., who also presented at the ISOP Conference. Dr. Holliday reported on a major statistical study conducted by RVO Senior Biostatistician Adam Roy, which investigated the factors that lead to patient happiness with their treatment for presbyopia. The findings indicated that restoration of near vision is essential to patient happiness, and that avoiding visual symptoms is of far greater importance than any impact on distance vision in the treated eye.
RVO also announced that Mr. Kilcoyne presented a company overview at the Ophthalmology Futures 2012 European Forum, which focused on ophthalmic innovation, financial expertise and corporate leadership and was also held in Milan, Italy.
The Raindrop Near Vision Inlay is implanted during a 10-minute procedure on the cornea on the non-dominant eye and microscopically changes the shape of the surface of that eye. The inlay is as transparent as natural tears and is less than half the thickness of a human hair. It is approximately 80% water and is bioengineered to facilitate transport of nutrients and fluid.
About ReVision Optics
ReVision Optics, Inc. focuses on the research and commercialization of custom optical solutions dedicated to presbyopic vision correction. RVO’s Raindrop™ Near Vision Inlay (formerly the Vue+® and PresbyLens®) offers a unique, patented refractive surgery solution. The inlay is designed to improve near vision that has been lost by the eye’s natural aging process called presbyopia. The Raindrop inlay provides an ideally suited surgical option for near and intermediate vision enhancement.
The Company is actively pursuing regulatory approvals and market opportunities for the Raindrop Near Vision Inlay worldwide. The Raindrop has received CE mark authorization and is available for sale in Europe.
CAUTION: Investigational device. Limited by U.S. Federal law to investigational use.